Logo for PTC Therapeutics Inc

PTC Therapeutics Investor Relations Material

Latest events

Logo for PTC Therapeutics Inc

Q3 2023

PTC Therapeutics
Logo for PTC Therapeutics

Q3 2023

26 Oct, 2023
Logo for PTC Therapeutics

Study Update

15 Sep, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company's commercial product is Emflaza (deflazacort) used for the treatment of Duchenne muscular dystrophy in ambulatory patients aged 5 years and older. Its lead product candidate is Translarna that is completed Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; which has completed Phase II/III clinical trials for the treatment of cystic fibrosis; and that is under preclinical development stage for the treatment of myotonic dystrophy type 1.